Intrastriatal lipopolysaccharide injection induces Parkinsonism in C57/B6 mice

Journal of Neuroscience Research

Volumn 87, Issue 8, 2009, Pages 1913-1921

  Hunter, Randy L ^a   Cheng, Baohua ^a,b   Choi, Dong Young ^a   Liu, Mei ^a   Liu, Shuwei ^b   Cass, Wayne A ^a   Bing, Guoying ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Inflammation; Neurodegeneration; Nitric oxide; Oxidative stress

Indexed keywords

CARBIDOPA; DOPAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LEVODOPA; LIPOPOLYSACCHARIDE; N(G) NITROARGININE; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; C57BL MOUSE; CELL DEATH; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DRUG ADMINISTRATION ROUTE; ENZYME SYNTHESIS; INFLAMMATION; INTRASTRIATAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NERVE DEGENERATION; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; DRUG EVALUATION, PRECLINICAL; ENCEPHALITIS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 66049127133     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22012     Document Type: Article

References (41)

1. Arimoto T, Bing G. 2003. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 12:35-45.
2. Beal MF. 2003. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991:120-131.
3. Berger JR. 2003. Von's Economo's encephalitis. In: Nath AB, editor. Clinical neurovirology. New York: Marcel Dekker. p 523-542.
4. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. 1999. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257.
5. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF. 2003. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984:133-142.
6. Castano A, Herrera AJ, Cano J, Machado A. 1998. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70:1584-1592.
7. Gao HM, Hong JS, Zhang W, Liu B. 2002. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782-790.
8. Goetz CG. 1999. Textbook of clinical neurology. Philadelphia: W.B. Saunders Co.
9. Hagg T, Varon S. 1993. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci U S A 90:6315-6319.
10. He Y, Appel S, Le W. 2001. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193.
11. Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB. 1999. Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta 1410:215-228.
12. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. 2000. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7:429-447.
13. Hornykiewicz O. 1993. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 60:140-147.
14. Hsieh PF, Chia LG, Ni DR, Cheng LJ, Ho YP, Tzeng SF, Chang MH, Hong JS. 2002. Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection. Neuroreport 13:277-280.
15. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363.
16. Hunter RL, Choi DY, Kincer JF, Cass WA, Bing G, Gash DM. 2007a. Fenbendazole treatment may influence lipopolysaccharide effects in rat brain. Comp Med 57:487-492.
17. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G. 2007b. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100:1375-1386.
18. Hunter RL, Liu M, Choi DY, Hardy PA, Bing G. 2007c. Inflammation and age related iron accumulation in F344 rats. Society for Neuroscience, San Diego, CA.
19. Hunter RL, Liu M, Choi DY, Cass WA, Bing G. 2008. Inflammation and age-related iron accumulation in F344 rats. Curr Aging Sci (in press).
20. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. 2002. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110:49-58.
21. Jenner P, Olanow CW. 1998. Understanding cell death in Parkinson's disease. Ann Neurol 44(Suppl 1):S72-S84.
22. Jones BJ, Roberts DJ. 1968. A rotarod suitable for quantitative measurements of motor incoordination in naive mice. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 259:211.
23. Knott C, Stern G, Wilkin GP. 2000. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16:724-739.
24. Lawson LJ, Perry VH, Dri P, Gordon S. 1990. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151-170.
25. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403-1409.
26. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS, Carvey PM. 2002. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 17:116-124.
27. Lu X, Bing G, Hagg T. 2000. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97:285-291.
28. McGeer PL, Itagaki S, Akiyama H, McGeer EG. 1988. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24:574-576.
29. McGeer PL, Yasojima K, McGeer EG. 2001. Inflammation in Parkinson's disease. Adv Neurol 86:83-89.
30. McRae-Degueurce A, Rosengren L, Haglid K, Booj S, Gottfries CG, Granerus AC, Dahlstrom A. 1988. Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases. Neurochem Res 13:679-684.
31. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-150.
32. Niehaus I. 2004. Lipopolysaccharides induce inflammation-mediated neurodegeneration in the substantia nigra and cerebral cortex (a case report). In: Hanin IFA, Cacabelos R, editors. New trends in Alzheimer and Parkinson related disorders. Bologna: Monduzzi Editore. p 36-39.
33. Parker WD Jr, Boyson SJ, Parks JK. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26:719-723.
34. Paxinos G. 2001. The mouse brain in stereotaxic coordinates,2nd ed. San Diego: Academic Press.
35. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55:453-462.
36. Rozas G, Guerra MJ, Labandeira-Garcia JL. 1997. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2:75-84.
37. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. 2006. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflamm 3:6.
38. West MJ. 1993. New stereological methods for counting neurons. Neurobiol Aging 14:275-285.
39. Yarkov AV, Hanger D, Reploge M, Joyce JN. 2003. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice. Pharmacol Biochem Behav 76:551-562.
40. Youdim MB, Riederer P. 1997. Understanding Parkinson's disease. Sci Am 276:52-59.
41. Zhang J, Stanton DM, Nguyen XV, Liu M, Zhang Z, Gash D, Bing G. 2005. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience 135:829-838.